Kolexia
Delaunay Jacques Hématologie
Delaunay Jacques
Hématologie
Societe D Hematologie Du Confluent
Nantes, France
236 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Syndromes myélodysplasiques Maladie du greffon contre l'hôte Tumeurs hématologiques Leucémie-lymphome lymphoblastique à précurseurs B et T Leucémie myélomonocytaire chronique Préleucémie

Collaborateurs

Voir plus
Chevallier Patrice
Chevallier Patrice
Hôpital Hôtel-Dieu Nantes, Nantes, France
Guillaume Thierry
Guillaume Thierry
Hôpital Hôtel-Dieu Nantes, Nantes, France
Mohty Mohamad
Mohty Mohamad
Hôpital Saint-Antoine, Paris, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Amgen
4 collaboration(s)
Dernière en 2021
Kappa Santé
2 collaboration(s)
Dernière en 2023
Janssen
2 collaboration(s)
Dernière en 2023
GSK
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
AVENHIR: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Abbvie)   02 janvier 2024
Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05
65th ASH Annual Meeting Abstracts   02 novembre 2023
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML): An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Merck & Co.)   20 octobre 2022
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
European journal of haematology   18 avril 2021
Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status.
European journal of haematology   27 mars 2021
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Haematologica   01 mars 2021
of NGS in management of haematological malignancies: experience after one year of routine in Eurofins-Biomnis laboratory
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference   01 décembre 2020
Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study
Blood   05 novembre 2020
IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Nephrology (Carlton, Vic.)   14 novembre 2019
Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies
Blood   13 novembre 2019